A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 16 01 2023
accepted: 17 04 2023
medline: 4 5 2023
pubmed: 2 5 2023
entrez: 2 5 2023
Statut: epublish

Résumé

Non-small cell lung cancer (NSCLC) represents 85% of all new lung cancer diagnoses and presents a high recurrence rate after surgery. Thus, an accurate prediction of recurrence risk in NSCLC patients at diagnosis could be essential to designate risk patients to more aggressive medical treatments. In this manuscript, we apply a transfer learning approach to predict recurrence in NSCLC patients, exploiting only data acquired during its screening phase. Particularly, we used a public radiogenomic dataset of NSCLC patients having a primary tumor CT image and clinical information. Starting from the CT slice containing the tumor with maximum area, we considered three different dilatation sizes to identify three Regions of Interest (ROIs): CROP (without dilation), CROP 10 and CROP 20. Then, from each ROI, we extracted radiomic features by means of different pre-trained CNNs. The latter have been combined with clinical information; thus, we trained a Support Vector Machine classifier to predict the NSCLC recurrence. The classification performances of the devised models were finally evaluated on both the hold-out training and hold-out test sets, in which the original sample has been previously divided. The experimental results showed that the model obtained analyzing CROP 20 images, which are the ROIs containing more peritumoral area, achieved the best performances on both the hold-out training set, with an AUC of 0.73, an Accuracy of 0.61, a Sensitivity of 0.63, and a Specificity of 0.60, and on the hold-out test set, with an AUC value of 0.83, an Accuracy value of 0.79, a Sensitivity value of 0.80, and a Specificity value of 0.78. The proposed model represents a promising procedure for early predicting recurrence risk in NSCLC patients.

Identifiants

pubmed: 37130116
doi: 10.1371/journal.pone.0285188
pii: PONE-D-23-01343
pmc: PMC10153708
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0285188

Informations de copyright

Copyright: © 2023 Bove et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Radiat Oncol. 2022 Apr 13;17(1):74
pubmed: 35418206
Sensors (Basel). 2022 Aug 31;22(17):
pubmed: 36081053
Ther Adv Med Oncol. 2017 Sep;9(9):599-609
pubmed: 29081843
Sci Rep. 2022 Nov 27;12(1):20366
pubmed: 36437296
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818782788
pubmed: 29940810
Cancers (Basel). 2022 Aug 04;14(15):
pubmed: 35954461
Nat Rev Clin Oncol. 2022 Feb;19(2):132-146
pubmed: 34663898
Front Genet. 2020 Aug 25;11:768
pubmed: 33193560
Sci Rep. 2022 May 12;12(1):7914
pubmed: 35552476
Cancers (Basel). 2021 Jul 19;13(14):
pubmed: 34298828
Med Biol Eng Comput. 2021 Jan;59(1):215-226
pubmed: 33411267
Sci Rep. 2020 Mar 13;10(1):4679
pubmed: 32170141
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Clin Cancer Res. 2019 Mar 1;25(5):1526-1534
pubmed: 30201760
J Cardiothorac Surg. 2021 May 12;16(1):128
pubmed: 33980268
Neurol Clin Neurophysiol. 2004 Nov 30;2004:37
pubmed: 16012598
Cancers (Basel). 2021 May 11;13(10):
pubmed: 34064923
J Digit Imaging. 2020 Aug;33(4):895-902
pubmed: 32333132
J Clin Med. 2022 Mar 16;11(6):
pubmed: 35329985
Eur Radiol. 2020 Jun;30(6):3528-3537
pubmed: 32055950
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
Cancers (Basel). 2022 Aug 27;14(17):
pubmed: 36077686
Transl Lung Cancer Res. 2020 Oct;9(5):2255-2276
pubmed: 33209648
Diagnostics (Basel). 2021 Jun 07;11(6):
pubmed: 34200270
Sci Data. 2018 Oct 16;5:180202
pubmed: 30325352
Sci Rep. 2019 Nov 21;9(1):17286
pubmed: 31754135
Annu Int Conf IEEE Eng Med Biol Soc. 2021 Nov;2021:3561-3564
pubmed: 34892008
In Vivo. 2018 Nov-Dec;32(6):1505-1512
pubmed: 30348709
Sci Rep. 2021 Jul 8;11(1):14123
pubmed: 34238968
Sci Rep. 2022 Aug 19;12(1):14132
pubmed: 35986072
Phys Med. 2021 Mar;83:9-24
pubmed: 33662856
Sci Robot. 2019 Dec 18;4(37):
pubmed: 33137719
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
Comput Med Imaging Graph. 2018 Jul;67:1-8
pubmed: 29660595
Acad Radiol. 2020 Apr;27(4):497-507
pubmed: 31285150
Sci Rep. 2020 Jul 23;10(1):12366
pubmed: 32703973
Sci Rep. 2020 Feb 6;10(1):1952
pubmed: 32029785
Ann Thorac Surg. 2020 Jun;109(6):1741-1749
pubmed: 32087134
EBioMedicine. 2022 Mar;77:103911
pubmed: 35248997
J Pers Med. 2022 Mar 16;12(3):
pubmed: 35330479
Comput Struct Biotechnol J. 2022 Apr 04;20:1811-1820
pubmed: 35521553
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Transl Lung Cancer Res. 2014 Aug;3(4):242-9
pubmed: 25806307
J Thorac Dis. 2016 Jan;8(1):152-60
pubmed: 26904224
Radiat Oncol. 2018 Oct 5;13(1):197
pubmed: 30290849
Clin Oncol (R Coll Radiol). 2021 Mar;33(3):145-154
pubmed: 32978027
J Pers Med. 2022 Jun 10;12(6):
pubmed: 35743737
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929

Auteurs

Samantha Bove (S)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Annarita Fanizzi (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Federico Fadda (F)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Maria Colomba Comes (MC)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Annamaria Catino (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Angelo Cirillo (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Cristian Cristofaro (C)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Michele Montrone (M)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Annalisa Nardone (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Pamela Pizzutilo (P)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Antonio Tufaro (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Domenico Galetta (D)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Raffaella Massafra (R)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH